|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00330616 |
This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics profile in elderly patients with depression.
Condition | Intervention | Phase |
Major Depressive Disorder |
Drug: 323U66 SR |
Phase III |
MedlinePlus related topics: | Depression |
ChemIDplus related topics: | Bupropion hydrochloride Bupropion |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Safety/Efficacy Study |
Official Title: | Clinical Evaluation of 323U66 SR in Patients With Depression - Investigation in Elderly Patients With Depression - |
Estimated Enrollment: | 30 |
Study Start Date: | May 2006 |
Study Completion Date: | November 2007 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Target disease: Patients diagnosed as having the following primary disease and current major depressive episode for at least 8 weeks on the basis of DSM-IV-TR criteria.
Exclusion criteria:
Patients who currently have or have a past history of the following disorders:
The index of seriousness is Grade 3 of "Criteria for classification of seriousness of adverse drug reactions to pharmaceutical products, etc." (PAB/PSD No.80 in 1992).
Japan | |||||
GSK Clinical Trials Call Center | |||||
Fukuoka city, Japan, 815 | |||||
GSK Clinical Trial Call Center | |||||
Kumamoto-city, Japan, 861 | |||||
GSK Clinical Trials Call Center | |||||
Tokyo, Japan, 189 | |||||
GSK Clinical Trials Call Center | |||||
Sapporo city, Japan, 005 | |||||
GSK Clinical Trials Call Center | |||||
Ibaraki, Japan, 303 | |||||
GSK Clinical Trial Call Center | |||||
Shirakawa city, Japan, 961 | |||||
GSK Clinical Trials Call Center | |||||
Kitaazumi-gun, Japan, 399 | |||||
GSK Clinical Trials Call Center | |||||
Iida-city, Japan, 395 | |||||
GSK Clinical Trials Call Center | |||||
Kawaguchi-city, Japan, 332 | |||||
GSK Clinical Trials Call Center | |||||
Tokyo, Japan, 170 | |||||
GSK Clinical Trials Call Center | |||||
Tokyo, Japan, 164 |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Study ID Numbers: | AK1102369 |
First Received: | May 26, 2006 |
Last Updated: | February 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00330616 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
|
|
|
|